BOSTON--(BUSINESS WIRE)--Attorneys from Mintz, Levin,Cohn, Ferris,Glovsky and Popeo, P.C. represented ImmunoGen, Inc. in a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners (TSSP).
In return for the payment to ImmunoGen, TSSP will have the right to receive 100% of the royalty revenue on Kadcyla commercial sales that would otherwise be paid by Roche to ImmunoGen until TSSP has received a total of either $235 million or $260 million, depending on timing. After this threshold is met, if ever, ImmunoGen will receive 85% of the Kadcyla royalty revenue and TSSP will receive 15% of the Kadcyla royalty revenue until this revenue stream ends.
Help employers find you! Check out all the jobs and post your resume.
In return for the payment to ImmunoGen, TSSP will have the right to receive 100% of the royalty revenue on Kadcyla commercial sales that would otherwise be paid by Roche to ImmunoGen until TSSP has received a total of either $235 million or $260 million, depending on timing. After this threshold is met, if ever, ImmunoGen will receive 85% of the Kadcyla royalty revenue and TSSP will receive 15% of the Kadcyla royalty revenue until this revenue stream ends.
Help employers find you! Check out all the jobs and post your resume.
